Inventor · disambiguated record
Amit Etkin
Also filed as: ETKIN AMIT
10 granted patents·24 pending applications·29 citations·filing 2012–2025
85Inventor score
Files withALTO NEUROSCIENCE INC19UNIV LELAND STANFORD JUNIOR11ALTOS NEUROSCIENCE INC1ETKIN AMIT1RIO GRANDE NEUROSCENCES INC1
Top patents by PatentIndex Score
34 records- 0192US11526808B2Machine learning based generation of ontology for structural and functional mappingUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Dec 13, 2022·10 cites·18 claims
- 0283US11577090B2Machine learning based artifact rejection for transcranial magnetic stimulation electroencephalogramUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Feb 14, 2023·8 cites·35 claims
- 0382US11324963B2Brain stimulation treatment in depressionUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted May 10, 2022·7 cites·22 claims
- 0481US12383196B2Treatment of depression using machine learningUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Aug 12, 2025·3 cites·17 claims
- 0578US12490933B2Treatment of depression using machine learningUNIV LELAND STANFORD JUNIOR·Filed 2025·Granted Dec 9, 2025·0 cites·17 claims
- 0678US12233059B2Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Granted Feb 25, 2025·0 cites·20 claims
- 0776US2025185987A1Treatment of depression using machine learningUNIV LELAND STANFORD JUNIOR·Filed 2025·Application pending·0 cites
- 0876US2025185989A1Treatment of depression using machine learningUNIV LELAND STANFORD JUNIOR·Filed 2025·Application pending·0 cites
- 0976US2025185988A1Treatment of depression using machine learningUNIV LELAND STANFORD JUNIOR·Filed 2025·Application pending·0 cites
- 1075US12208096B2Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Granted Jan 28, 2025·0 cites·12 claims
- 1173US12150777B2Treatment of depressionUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Nov 26, 2024·1 cites·15 claims
- 1272US12226375B1Method of treatment and selection of patients benefiting from agomelatine based on EEG measurementsALTO NEUROSCIENCE INC·Filed 2024·Granted Feb 18, 2025·0 cites·17 claims
- 1370US2025009738A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1469US2024307377A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1566US12115383B2Brain stimulation treatment in depressionUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Oct 15, 2024·0 cites·22 claims
- 1664US2024307376A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1764US2025144092A1Treatment of psychiatric or neurological disorders in patients with prominent anhedonia using irdabisant as a monotherapy or in combination with an antipsychotic agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1863US2024316016A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1963US2023117508A1Enhancement of camp signaling as a combination drug strategy for the treatment of psychiatric and neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction existsALTO NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 2062US2025120957A1Treatment of neuropsychiatric disorders with tilivapramALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2161US2024342165A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2261US2024307378A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2359US2024197721A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2023·Application pending·0 cites
- 2458US2024342164A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2558US2025177387A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 2658US2022226302A1Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditionsALTOS NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 2755US2025177386A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 2854US2022387424A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 2952US2025177331A1Method of treatment and selection of patients benefiting from agomelatine based on eeg measurementsALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 3049US2022226331A1Integration of molecular mechanisms in the striatum as a combination drug strategy for the treatment of psychiatric and neurological disorders in which anhedonia or motivation-related dysfunction existsALTO NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 3140US2013102918A1System and method for diagnosing and treating psychiatric disordersETKIN AMIT·Filed 2012·Application pending·0 cites
- 3236US2019083805A1Detecting or treating post-traumatic stress syndromeUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 3334US2018236255A1Neurostimulation treatmentTHE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIV·Filed 2018·Application pending·0 cites
- 3434US2017106203A1Control of spike-timing dependent brain network plasticity via multi-coil transcranial magnetic stimulationRIO GRANDE NEUROSCENCES INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Amit Etkin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →